Skip to main
DGX
DGX logo

Quest Diagnostics (DGX) Stock Forecast & Price Target

Quest Diagnostics (DGX) Analyst Ratings

Based on 27 analyst ratings
Buy
Strong Buy 26%
Buy 19%
Hold 48%
Sell 4%
Strong Sell 4%

Bulls say

Quest Diagnostics Inc. demonstrates a positive growth trajectory, with its revenue reaching $2.62 billion, representing a year-over-year increase of 14.5% and organic growth of approximately 5%. The company's consumer-initiated testing segment is particularly strong, posting nearly $60 million in revenue for the fourth quarter alone and contributing to almost $100 million in total revenue, with the introduction of approximately 135 new tests. Additionally, management anticipates an expansion of operating margins in 2025 and has projected robust cash flow from operations of $1.45 billion, suggesting ongoing financial stability and capacity for capital deployment.

Bears say

Quest Diagnostics Inc is facing several financial headwinds that contribute to a negative outlook for the company's stock. Key factors include an approximate $0.20 per share impact related to investments in modernizing its IT infrastructure and compliance with Laboratory Developed Test (LDT) regulations, as well as a $0.50 per share impact from increased year-over-year interest expenses. Additionally, despite a potential ongoing tailwind from its advanced diagnostics menu, the mixed hospital backdrop suggests challenges in market demand that could further dampen revenue growth.

Quest Diagnostics (DGX) has been analyzed by 27 analysts, with a consensus rating of Buy. 26% of analysts recommend a Strong Buy, 19% recommend Buy, 48% suggest Holding, 4% advise Selling, and 4% predict a Strong Sell.

This aggregate rating is based on analysts' research of Quest Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Quest Diagnostics (DGX) Forecast

Analysts have given Quest Diagnostics (DGX) a Buy based on their latest research and market trends.

According to 27 analysts, Quest Diagnostics (DGX) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $148.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $148.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Quest Diagnostics (DGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.